Molecular Docking Analysis of Resveratrol and Macrolide Antibiotics for the Treatment of Porhyromonas gingivalis-Associated Periodontitis
Anatolian Journal of Pharmaceutical Sciences · 2025
DOI: 10.71133/anatphar.1730860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anatolian Journal of Pharmaceutical Sciences, 2025. Verfasst von Didem Mimiroğlu und 1 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Periodontitis is a chronic inflammatory disease that can be caused by a major contributor, the Gram-negative bacterium Porphyromonas gingivalis (P. gingivalis). While macrolide antibiotics are widely used for treatment and demonstrate their activity by targeting the 23S rRNA region of bacterial ribosomes, their long-term use can lead to antibiotic resistance and compromise the balance of beneficial microbiota within the human body. For this reason, various natural compounds such as resveratrol (RSV) can be studied as an alternative for the treatment. While many studies have investigated the use of RSV in treating P. gingivalis-associated periodontitis, the molecular interactions between RSV and the ribosomal binding sites remain open to issue. Therefore, the study aims to investigate the binding interactions between RSV, the macrolide antibiotics, and the 23S rRNA region of bacterial ribosomes (nucleotides 2040-2080) using molecular docking analysis. The results showed that erythromycin and azithromycin had high binding affinities of -7.47 and -7.15 kcal/mol, respectively, with ribosomal binding sites, forming hydrogen bonds with ADE2069 and ADE2071. In contrast, RSV demonstrated a docking score of -6.10 kcal/mol, exhibiting similar interactions to macrolide antibiotics. Additionally, the results indicated that the docking score of RSV was less negative (approximately 1.05 to 1.36 kcal/mol) in comparison to these macrolides. The obtained result was in line with the reported binding energies (from -5.63 to -6.85 kcal/mol) for FDA-approved drugs. As a result, RSV may serve as a promising therapeutic candidate for the treatment of periodontal diseases.
Zitieren
APA
Mimiroğlu, D., & Zabcı, S. (2025). Molecular Docking Analysis of Resveratrol and Macrolide Antibiotics for the Treatment of Porhyromonas gingivalis-Associated Periodontitis. Anatolian Journal of Pharmaceutical Sciences. https://doi.org/10.71133/anatphar.1730860
Vancouver
Mimiroğlu D, Zabcı S. Molecular Docking Analysis of Resveratrol and Macrolide Antibiotics for the Treatment of Porhyromonas gingivalis-Associated Periodontitis. Anatolian Journal of Pharmaceutical Sciences. 2025. doi:10.71133/anatphar.1730860
BibTeX
@article{Mimirolu2025,
author = {Mimiroğlu, Didem and Zabcı, Sema},
title = {Molecular Docking Analysis of Resveratrol and Macrolide Antibiotics for the Treatment of Porhyromonas gingivalis-Associated Periodontitis},
journal = {Anatolian Journal of Pharmaceutical Sciences},
year = {2025},
doi = {10.71133/anatphar.1730860}
}
EUVIMED